Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat ADHD (US)

Analysis of: Medicare fees to doctors fall Tuesday (news.yahoo.com)
Your mother and father will not get the compassion and care when they call for medical help .   It will not be available.  Your family physician was financially forced to leave.
Analysis of: Why anaesthetics can make the pain worse (www.newscientist.com)
Pain is a complex of the personal, subjective, and unpleasant experiences  that may or may  not be related to physical injury or tissue damage.  It has been described “timeless, ineluctable, and disconcertingly indefinable.”  The expression may be influenced by psychosocial, ...
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: Interim report for the first quarter of 2008 - strong growth in sales and profits (www.lundbeck.com)
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
June 30, 2008
Who cares?
Analysis of: Taro Receives Final FDA Approval For RX Cetirizine Hydrochloride Syrup ANDA (www.medicalnewstoday.com)
Taro just got approval for Rx cetirizine - big whoop!  Zyrtec has been OTC in all forms (tablet, chewable and syrup) since 11/07.  Do you know anyone who will write a prescription for an OTC drug or an insurance company that will cover it?
Analysis of: Doctors Say Medication Is Overused in Dementia (www.nytimes.com)
We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.
Analysis of: FDA Approves GlaxoSmithKline's New Combination Vaccine For Children (www.medicalnewstoday.com)
Glaxo has just gotten approval for Kinrix (DTaP-IPV).  It's products for infants and toddlers, Pediarix (DTaP-HepB-IPV) and Infanrix (DTaP) are used in children under 2; Kinrix will be used for the 4-6 year booster dose, reducing by 1 the number of vacthat children get at this age.
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
Analysis of: FDA's Chief Scientist Asks Science Board Subcommittee To Review Research On Bisphenol-A (www.medicalnewstoday.com)
The FDA is opening investigations into whether the widely used plastic additive bisphenol A may have various effects on humans, based on animal models. Several companies are already touting their "BPA-free" status; as the FDA investigation will take a prolonged period to review and summarize available...
Analysis of: Datacsope stock soars on takeover tlaks (www.northjersey.com)
-Datascope has decided to exit the monitor market by selling a chunk of itself off, possibly making itself into a takeover candidate.  The remaining units make stents, balloon catheters and other cardiac equipment.  -One other effect is that it has placed itself into direct (rather than indirect)...
Analysis of: Novartis presents full pipeline of novel vaccines addressing significant unmet needs (www.pipelinereview.com)
-Novartis' press conference discussed a "full pipline" of new vaccines, but the majority are still Phase I. -The meningitis vaccines being developed are not yet ready to go, and the one that is closest to being filed already has a competitor on the market.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 540

Analytics


Generated at 2009-01-07T19:00:58.307